CACNG6

Summary

CACNG6 (calcium voltage-gated channel auxiliary subunit gamma 6, HGNC:13625) is a protein-coding gene on chromosome 19q13.42, encoding Voltage-dependent calcium channel gamma-6 subunit (Q9BXT2). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit.

Voltage-dependent calcium channels are composed of five subunits. The protein encoded by this gene represents one of these subunits, gamma, and is one of two known gamma subunit proteins. This particular gamma subunit is an integral membrane protein that is thought to stabilize the calcium channel in an inactive (closed) state. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members that function as transmembrane AMPA receptor regulatory proteins (TARPs). Alternative splicing results in multiple transcript variants. Variants in this gene have been associated with aspirin-intolerant asthma.

Source: NCBI Gene 59285 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 69 total — 1 pathogenic
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_145814

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13625
Approved symbol	CACNG6
Name	calcium voltage-gated channel auxiliary subunit gamma 6
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000130433
Ensembl biotype	protein_coding
OMIM	606898
Entrez	59285

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000252729, ENST00000346968, ENST00000352529, ENST00000955412

RefSeq mRNA: 3 — MANE Select: NM_145814 NM_031897, NM_145814, NM_145815

CCDS: CCDS12870, CCDS12871

Canonical transcript exons

ENST00000252729 — 4 exons

Exon	Start	End
ENSE00000895267	53999634	53999771
ENSE00000895269	53998239	53998313
ENSE00001854002	54011951	54012666
ENSE00003915662	53991637	53993208

Expression profiles

Bgee: expression breadth ubiquitous, 124 present calls, max score 93.29.

FANTOM5 (CAGE): breadth broad, TPM avg 0.5243 / max 49.8471, expressed in 191 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177458	0.4603	173
177459	0.0640	25

Top tissues by expression

216 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
hindlimb stylopod muscle	UBERON:0004252	93.29	gold quality
gastrocnemius	UBERON:0001388	93.15	gold quality
muscle of leg	UBERON:0001383	91.32	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	88.16	gold quality
sperm	CL:0000019	87.45	silver quality
right uterine tube	UBERON:0001302	87.07	gold quality
tibialis anterior	UBERON:0001385	86.63	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	84.48	gold quality
skeletal muscle tissue	UBERON:0001134	83.62	gold quality
mucosa of paranasal sinus	UBERON:0005030	82.48	silver quality
superficial temporal artery	UBERON:0001614	81.07	gold quality
quadriceps femoris	UBERON:0001377	78.59	silver quality
vastus lateralis	UBERON:0001379	77.61	silver quality
deltoid	UBERON:0001476	77.54	silver quality
biceps brachii	UBERON:0001507	77.04	gold quality
muscle tissue	UBERON:0002385	76.69	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	75.00	silver quality
oocyte	CL:0000023	73.26	silver quality
bronchial epithelial cell	CL:0002328	72.97	gold quality
upper leg skin	UBERON:0004262	72.67	gold quality
bronchus	UBERON:0002185	72.30	gold quality
nasal cavity mucosa	UBERON:0001826	70.69	gold quality
gingival epithelium	UBERON:0001949	68.74	gold quality
skin of hip	UBERON:0001554	67.74	gold quality
gingiva	UBERON:0001828	65.41	gold quality
nasal cavity epithelium	UBERON:0005384	64.93	gold quality
right lung	UBERON:0002167	63.37	gold quality
body of tongue	UBERON:0011876	63.22	gold quality
cardia of stomach	UBERON:0001162	62.65	silver quality
germinal epithelium of ovary	UBERON:0001304	62.40	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting CACNG6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-6760-5P	98.87	66.73	1515
HSA-MIR-7851-3P	98.72	64.88	980
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-6878-5P	98.49	67.91	2142
HSA-MIR-4691-3P	98.11	66.83	1204
HSA-MIR-204-3P	97.80	66.84	1656
HSA-MIR-4733-5P	97.75	67.44	866
HSA-MIR-8089	97.74	66.21	1698
HSA-MIR-296-5P	97.61	64.02	851
HSA-MIR-4667-5P	97.61	66.67	1683
HSA-MIR-493-3P	97.50	66.44	731
HSA-MIR-558	97.50	67.16	977
HSA-MIR-3184-3P	96.96	66.91	845
HSA-MIR-3059-3P	96.71	67.08	606
HSA-MIR-3675-5P	95.90	65.80	474
HSA-MIR-6835-5P	95.81	64.27	500
HSA-MIR-1282	91.07	71.26	99

Literature-anchored findings (GeneRIF, showing 2)

• CACNG6 variants might be associated with the risk of aspirin-intolerant asthma in a Korean population. (PMID:20860846)
• These results indicate that CACNG4, CACNG5, CACNG6 and CACNG8 may contribute to the risk of SCZ. The statistical epistasis identified between CACNG5 and CACNG6 suggests that there may be an underlying biological interaction between the two genes. (PMID:27102562)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cacng6a	ENSDARG00000036457
danio_rerio	cacng6b	ENSDARG00000046079
mus_musculus	Cacng6	ENSMUSG00000078815
rattus_norvegicus	Cacng6	ENSRNOG00000063051

Paralogs (1): CACNG1 (ENSG00000108878)

Protein

Protein identifiers

Voltage-dependent calcium channel gamma-6 subunit — Q9BXT2 (reviewed: Q9BXT2)

Alternative names: Neuronal voltage-gated calcium channel gamma-6 subunit

All UniProt accessions (3): Q9BXT2, A6NFR2, A6NP74

UniProt curated annotations — full annotation on UniProt →

Function. Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit.

Subunit / interactions. Interacts with CACNA1C. Identified in a complex with the L-type calcium channel subunits CACNA1C, CACNA2D1 and either CACNB1 or CACNB2.

Subcellular location. Cell membrane.

Tissue specificity. Detected in heart left ventricle.

Similarity. Belongs to the PMP-22/EMP/MP20 family. CACNG subfamily.

RefSeq proteins (3): NP_114103, NP_665813, NP_665814 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004031	PMP22/EMP/MP20/Claudin	Family
IPR008368	VDCC_gsu	Family
IPR008370	VDCC_g6su	Family

Pfam: PF13903

UniProt features (8 total): transmembrane region 4, chain 1, region of interest 1, compositionally biased region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BXT2-F1	76.94	0.30

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-5576892	Phase 0 - rapid depolarisation
R-HSA-5576893	Phase 2 - plateau phase
R-HSA-397014	Muscle contraction
R-HSA-5576891	Cardiac conduction

MSigDB gene sets: 93 (showing top): KEGG_MAPK_SIGNALING_PATHWAY, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_CALCIUM_ION_TRANSMEMBRANE_TRANSPORT, ROZANOV_MMP14_TARGETS_UP, GOBP_REGULATION_OF_TRANSPORT, GOBP_CALCIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_REGULATION_OF_MONOATOMIC_ION_TRANSPORT, GOBP_TRANSMEMBRANE_TRANSPORT, KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC, AP4_01, GOBP_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOCC_VOLTAGE_GATED_CALCIUM_CHANNEL_COMPLEX, GOCC_CATION_CHANNEL_COMPLEX, GOCC_TRANSPORTER_COMPLEX, GOCC_MEMBRANE_PROTEIN_COMPLEX

GO Biological Process (5): calcium ion transport (GO:0006816), regulation of calcium ion transmembrane transport via high voltage-gated calcium channel (GO:1902514), monoatomic ion transport (GO:0006811), monoatomic ion transmembrane transport (GO:0034220), calcium ion transmembrane transport (GO:0070588)

GO Molecular Function (3): voltage-gated calcium channel activity (GO:0005245), calcium channel regulator activity (GO:0005246), calcium channel activity (GO:0005262)

GO Cellular Component (5): plasma membrane (GO:0005886), voltage-gated calcium channel complex (GO:0005891), L-type voltage-gated calcium channel complex (GO:1990454), membrane (GO:0016020), monoatomic ion channel complex (GO:0034702)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cardiac conduction	2
Muscle contraction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
calcium channel activity	2
metal ion transport	1
calcium ion transmembrane transport via high voltage-gated calcium channel	1
regulation of calcium ion transmembrane transport	1
transport	1
monoatomic ion transport	1
transmembrane transport	1
calcium ion transport	1
monoatomic cation transmembrane transport	1
voltage-gated monoatomic cation channel activity	1
ion channel regulator activity	1
monoatomic cation channel activity	1
calcium ion transmembrane transporter activity	1
membrane	1
cell periphery	1
calcium channel complex	1
plasma membrane protein complex	1
voltage-gated calcium channel complex	1
T-tubule	1
cellular anatomical structure	1
transmembrane transporter complex	1

Protein interactions and networks

STRING

357 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CACNG6	CACNB4	O00305	503
CACNG6	CACNA2D3	Q8IZS8	487
CACNG6	CACNB2	Q08289	486
CACNG6	ATP2A1	O14983	474
CACNG6	KCNS2	Q9ULS6	356
CACNG6	LRTM1	Q9HBL6	353
CACNG6	FSIP1	Q8NA03	324
CACNG6	ILDR2	Q71H61	311
CACNG6	KCNK15	Q9H427	309
CACNG6	KCNA7	Q96RP8	301
CACNG6	TCTN3	Q6NUS6	300
CACNG6	KCNU1	A8MYU2	275
CACNG6	KCNK13	Q9HB14	273
CACNG6	BAIAP3	O94812	272
CACNG6	PLA2G4E	Q3MJ16	272

IntAct

5 interactions, top by confidence:

A	B	Type	Score
CACNG6	HSPD1	psi-mi:“MI:0915”(physical association)	0.400
	TMEM223	psi-mi:“MI:0914”(association)	0.350
PRR27	VWA8	psi-mi:“MI:0914”(association)	0.350
CACNG6	TSPAN3	psi-mi:“MI:0914”(association)	0.350

BioGRID (34): CACNG6 (Affinity Capture-MS), CACNG6 (Proximity Label-MS), CDS1 (Affinity Capture-MS), SLC5A3 (Affinity Capture-MS), CACNG6 (Affinity Capture-MS), FITM2 (Affinity Capture-MS), TNPO3 (Affinity Capture-MS), MSMO1 (Affinity Capture-MS), XPO6 (Affinity Capture-MS), SLC7A2 (Affinity Capture-MS), GOLGA5 (Affinity Capture-MS), MFSD5 (Affinity Capture-MS), SLC38A3 (Affinity Capture-MS), LGALS3 (Affinity Capture-MS), TTYH3 (Affinity Capture-MS)

ESM2 similar proteins: A0A1D5NY17, A4IF75, B2RVY9, B3SHH9, F6V1J6, O42281, O70578, P19518, P97707, Q06432, Q08CE6, Q08DE1, Q0D289, Q0V9E0, Q14714, Q2MJQ7, Q4R4Z3, Q4V922, Q5CZV0, Q5PRC1, Q5RDV7, Q5XGU1, Q62147, Q66IV3, Q68FV0, Q6AZD1, Q6P0C6, Q6R5J2, Q6ZP80, Q6ZUX7, Q7ZZL8, Q86WI0, Q8BGA2, Q8NBL3, Q8VHW3, Q8VHW4, Q8VHW7, Q8VHW8, Q91Y55, Q925N4

Diamond homologs: O70578, P19518, P97707, Q06432, Q08DE1, Q2MJQ7, Q8VHW3, Q8VHW7, Q9BXT2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

69 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	61
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
253434	GRCh37/hg19 19q13.42(chr19:54280799-54635178)x1	Pathogenic

SpliceAI

636 predictions. Top by Δscore:

Variant	Effect	Δscore
19:53998228:T:A	acceptor_gain	1.0000
19:53998237:A:AG	acceptor_gain	1.0000
19:53998238:G:GA	acceptor_gain	1.0000
19:53998238:GA:G	acceptor_gain	1.0000
19:53998238:GAA:G	acceptor_gain	1.0000
19:53998238:GAAGC:G	acceptor_gain	1.0000
19:53998309:GAAAG:G	donor_gain	1.0000
19:53998314:G:T	donor_loss	1.0000
19:54011945:CCGCA:C	acceptor_loss	1.0000
19:54011946:CGCAG:C	acceptor_loss	1.0000
19:54011947:GCA:G	acceptor_loss	1.0000
19:54011948:CAGG:C	acceptor_loss	1.0000
19:54011949:A:AC	acceptor_loss	1.0000
19:54011949:A:AG	acceptor_gain	1.0000
19:54011950:G:GT	acceptor_gain	1.0000
19:54011950:GGC:G	acceptor_gain	1.0000
19:54011950:GGCCT:G	acceptor_gain	1.0000
19:53999625:T:TA	acceptor_gain	0.9900
19:54011946:C:A	acceptor_gain	0.9900
19:54011949:AG:A	acceptor_gain	0.9900
19:54011950:GG:G	acceptor_gain	0.9900
19:54011950:GGCC:G	acceptor_gain	0.9900
19:53998236:C:G	acceptor_gain	0.9800
19:53999628:T:A	acceptor_gain	0.9800
19:53999631:CAG:C	acceptor_gain	0.9800
19:53999632:AGA:A	acceptor_gain	0.9800
19:53999633:GAG:G	acceptor_gain	0.9800
19:53999725:TGCA:T	donor_gain	0.9800
19:53999726:GCAG:G	donor_gain	0.9800
19:53999767:CTCAG:C	donor_loss	0.9800

AlphaMissense

1631 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:53993129:G:C	W84C	0.996
19:53993129:G:T	W84C	0.996
19:53993127:T:A	W84R	0.995
19:53993127:T:C	W84R	0.995
19:53993058:T:C	F61L	0.994
19:53993060:C:A	F61L	0.994
19:53993060:C:G	F61L	0.994
19:53993144:G:C	K89N	0.992
19:53993144:G:T	K89N	0.992
19:53993184:T:A	C103S	0.992
19:53993185:G:A	C103Y	0.992
19:53993185:G:C	C103S	0.992
19:53998247:T:A	C114S	0.991
19:53998248:G:C	C114S	0.991
19:54011968:A:C	S188R	0.991
19:54011970:C:A	S188R	0.991
19:54011970:C:G	S188R	0.991
19:53993137:G:A	C87Y	0.990
19:53993138:C:G	C87W	0.990
19:53993184:T:C	C103R	0.989
19:53998248:G:A	C114Y	0.989
19:53993121:G:A	G82R	0.988
19:53993121:G:C	G82R	0.988
19:53993122:G:A	G82E	0.988
19:53998249:C:G	C114W	0.988
19:53993187:G:T	G104C	0.987
19:53998257:T:G	F117C	0.987
19:53993022:G:C	G49R	0.986
19:53993063:G:C	W62C	0.986
19:53993063:G:T	W62C	0.986

dbSNP variants (sampled 300 via entrez): RS1000047377 (19:53999673 T>C), RS1000190008 (19:54006620 C>T), RS1000201341 (19:54006233 G>C), RS1000240971 (19:53991552 G>T), RS1000355786 (19:54012557 C>T), RS1000397291 (19:53999994 G>A), RS1000486907 (19:53996784 T>C), RS1000524202 (19:54004669 C>G), RS1000535634 (19:54004464 C>A,G,T), RS1000598830 (19:54011560 A>T), RS1000711919 (19:54002082 T>G), RS1000744436 (19:54002266 G>A,T), RS1000946960 (19:54006844 TTATTTTGTTA>T), RS1000992544 (19:53995890 G>C), RS1001094663 (19:54010944 T>C)

Disease associations

OMIM: gene MIM:606898 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2363032 (PROTEIN COMPLEX GROUP)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 67,947 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1428	NIMODIPINE	4	32,587
CHEMBL95	TACRINE	4	35,360

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

58 potent at pChembl≥5 of 75 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.82	IC50	1.5	nM	CHEMBL3891844
8.72	IC50	1.9	nM	CHEMBL3890624
8.62	IC50	2.4	nM	CHEMBL3973392
8.57	IC50	2.7	nM	CHEMBL3891844
8.52	IC50	3	nM	CHEMBL3919024
8.51	IC50	3.1	nM	CHEMBL3919898
8.35	IC50	4.5	nM	CHEMBL3965812
8.23	IC50	5.9	nM	CHEMBL3906126
8.22	IC50	6	nM	CHEMBL3890916
8.15	IC50	7	nM	CHEMBL3940577
8.14	IC50	7.2	nM	CHEMBL3969562
8.12	IC50	7.6	nM	CHEMBL3937280
8.12	IC50	7.6	nM	CHEMBL3965812
8.10	IC50	8	nM	CHEMBL3983323
8.05	IC50	9	nM	CHEMBL3942512
8.03	IC50	9.4	nM	CHEMBL3922498
8.01	IC50	9.7	nM	CHEMBL3897303
7.96	IC50	11	nM	CHEMBL3948329
7.92	IC50	12	nM	CHEMBL3898359
7.85	IC50	14	nM	CHEMBL3911369
7.85	IC50	14	nM	CHEMBL3913505
7.85	IC50	14	nM	CHEMBL3936725
7.82	IC50	15	nM	CHEMBL3984596
7.82	IC50	15	nM	CHEMBL3902376
7.67	IC50	21.5	nM	CHEMBL3952905
7.62	IC50	24	nM	CHEMBL3972896
7.58	IC50	26	nM	CHEMBL3889804
7.55	IC50	28	nM	CHEMBL3958844
7.55	IC50	28	nM	CHEMBL3973382
7.52	IC50	30	nM	CHEMBL3978200
7.52	IC50	30	nM	CHEMBL3985660
7.51	IC50	31	nM	CHEMBL3896861
7.51	IC50	31	nM	CHEMBL3951956
7.50	IC50	31.4	nM	CHEMBL3962403
7.44	IC50	36	nM	CHEMBL3953976
7.44	IC50	36	nM	CHEMBL3925140
7.41	IC50	39	nM	CHEMBL3900691
7.39	IC50	41	nM	CHEMBL3930781
7.30	IC50	50	nM	CHEMBL3921840
7.21	IC50	62	nM	CHEMBL3956991
7.17	IC50	67	nM	CHEMBL3965293
7.09	IC50	81	nM	CHEMBL3958264
7.07	IC50	85	nM	CHEMBL3964411
7.01	IC50	98.5	nM	CHEMBL3953031
6.40	IC50	400	nM	CHEMBL3974355
6.10	IC50	800	nM	CHEMBL3734797
5.75	IC50	1800	nM	CHEMBL4228929
5.66	IC50	2200	nM	CHEMBL4226021
5.52	IC50	3000	nM	CHEMBL4228209
5.52	IC50	3000	nM	CHEMBL4224773

PubChem BioAssay actives

13 with measured affinity, of 101 total; 13 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-tert-butyl-8-[[[(1S,2S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarbonyl]amino]methyl]-5-[3-(trifluoromethoxy)phenyl]-3,4-dihydro-1H-isoquinoline-2-carboxamide	1262825: Inhibition of voltage-gated calcium channel (unknown origin)	ic50	0.8000	uM
5-methyl-1-[(2-nitrophenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	1.8000	uM
1-[(3-chlorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	2.2000	uM
5-methyl-1-[(3-nitrophenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.0000	uM
1-[(4-chlorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.0000	uM
1-benzyl-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.4000	uM
5-methyl-1-[(4-methylphenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.6000	uM
1-[(4-fluorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	4.8000	uM
N-heptyl-16,18-dioxo-17-azapentacyclo[6.6.5.02,7.09,14.015,19]nonadeca-2,4,6,9,11,13-hexaene-1-carboxamide	1612587: Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay	ic50	9.0000	uM
ethyl 5-amino-4-(3-methoxyphenyl)-2-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	9.0000	uM
ethyl 5-amino-4-(3,4-dimethoxyphenyl)-2-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	9.0000	uM
propan-2-yl 5-amino-2-methyl-4-phenyl-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	10.0000	uM
ethyl 5-amino-2-methyl-4-phenyl-6,7,8,9,10,11-hexahydrocycloocta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	10.0000	uM

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation	2
Cisplatin	increases expression, affects expression, affects cotreatment	2
Particulate Matter	decreases expression, increases abundance, affects expression	2
afuresertib	increases expression	1
methylethyl ketone	decreases expression	1
deoxynivalenol	decreases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
polyhexamethyleneguanidine	affects expression	1
CGP 52608	increases reaction, affects binding	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Decitabine	affects expression	1
Air Pollutants	decreases expression, increases abundance	1
Aspirin	affects response to substance	1
Cannabinoids	increases abundance, affects methylation	1
Diethylhexyl Phthalate	decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
Methapyrilene	increases methylation	1
Pesticides	increases methylation	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	decreases expression	1
Valproic Acid	affects cotreatment, increases expression	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3737861	Binding	Inhibition of voltage-gated calcium channel (unknown origin)	Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7LF	Ubigene A-549 CACNG6 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.